1. Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS. Issue 3 (June 2015) Authors: Miller, Robert G.; Block, Gilbert; Katz, Jonathan S.; Barohn, Richard J.; Gopalakrishnan, Vidhya; Cudkowicz, Merit; Zhang, Jane R.; McGrath, Michael S.; Ludington, Elizabeth; Appel, Stan H.; Azhir, Ari; Katz, Jonathan; Kushner, Giovanna; Wong, Cynthia; Engel, Maguerite; Forshew, Dallas; Osborne, ... Journal: Neurology Issue: Volume 2:Issue 3(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. Issue 7 (December 2014) Authors: Miller, Robert G.; Zhang, Rongzhen; Block, Gilbert; Katz, Jonathan; Barohn, Richard; Kasarskis, Edward; Forshew, Dallas; Gopalakrishnan, Vidhya; McGrath, Michael S. Journal: Amyotrophic lateral sclerosis and frontotemporal degeneration Issue: Volume 15:Issue 7/8(2014) Page Start: 601 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗